Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine aced a ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... heart failure in 2021 and secured an expanded label in a hard-to-treat population the next year.

It does not provide Zepbound for people whose doctors have prescribed it off-label. Off-label means that a doctor prescribes a medication for a reason or at a dose the FDA has not approved.

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...